News Ionis hit by safety concerns, rivals Alnylam benefit Biotech insists drug for rare inherited disorder is still approvable.
Cancer AZ confirms move to acquire cancer specialist Acerta Acerta brings with it a promising lead candidate
News BMS's Breyanzi is first CAR-T for marginal zone lymphoma Bristol Myers Squibb has taken CAR-T therapy into new territory, after getting FDA approval for Breyanzi in marginal zone lymphoma.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
